Date:10/19/2009

2,155 2,158 0% 3% Peripheral Interventions 493 520 (6)% (2)% --- --- --- --- Cardiovascular Group 2,648 2,678 (1)% 2% Neurovascular 259 272 (4)% (1)% Endoscopy 737 710 4% 7% Urology/Gynecology 333 318 5% 6% --- --- --- --- Endosurgery Group 1,070 1,028 4% 7% Neuromodulation 205 177 16% 16% --- --- --- --- Subtotal 6,100 5,986 2% 5% Divested Businesses 9 62 N/A N/A Worldwide $6,109 $6,048 1% 4% ====== ====== === === Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. An explanation of the Company's use of these non-GAAP measures is provided at the end of this document. BOSTON SCIENTIFIC CORPORATION NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS (Unaudited) Q3 2009 YTD Net Sales as compared to Q3 2008 YTD ------------------------------------------------ Change ------ Estimated As Reported Constant Impact of Currency Currency Foreign Basis Basis C
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Related medicine technology :

1. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
2. Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Covered Stents
3. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
4. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
5. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
6. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
7. Boston Scientific Announces Schedule for European Society of Cardiology Congress
8. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
9. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
10. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials